Valuation: PharmaEngine, Inc.

Market Cap 795.97Cr 25Cr 22Cr 21Cr 19Cr 36Cr 2.4TCr 36Cr 250.76Cr 97Cr 1.23TCr 94Cr 92Cr 3.94TCr P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 328.5Cr 10Cr 9.16Cr 8.55Cr 7.79Cr 15Cr 991.37Cr 15Cr 103.49Cr 40Cr 506.8Cr 39Cr 38Cr 1.63TCr EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.29%
Yield 2024
6.64%
Yield 2025 2.84%
1 day+0.18%
1 week-0.18%
Current month-0.36%
1 month-3.99%
3 months-9.18%
6 months-6.10%
Current year-21.31%
1 week 55.1
Extreme 55.1
56
1 month 53.9
Extreme 53.9
58.5
Current year 53
Extreme 53
74
1 year 53
Extreme 53
74.4
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 15/05/2018
Director/Board Member - 13/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%-0.18%-17.56%-37.19% 25Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.18%-0.55%+47.19%+104.53% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+58.72%+129.80%

Financials

2024 2025
Net sales 252.33Cr 7.92Cr 7.04Cr 6.57Cr 5.99Cr 11Cr 761.49Cr 11Cr 79Cr 31Cr 389.28Cr 30Cr 29Cr 1.25TCr 91Cr 2.86Cr 2.54Cr 2.37Cr 2.16Cr 4.08Cr 275.05Cr 4.12Cr 29Cr 11Cr 140.61Cr 11Cr 11Cr 451.26Cr
Net income 175.1Cr 5.5Cr 4.88Cr 4.56Cr 4.15Cr 7.84Cr 528.43Cr 7.91Cr 55Cr 21Cr 270.14Cr 21Cr 20Cr 866.98Cr 39Cr 1.22Cr 1.08Cr 1.01Cr 91.98L 1.73Cr 116.98Cr 1.75Cr 12Cr 4.73Cr 60Cr 4.57Cr 4.47Cr 191.93Cr
Net Debt -385.37Cr -12Cr -11Cr -10Cr -9.14Cr -17Cr -1.16TCr -17Cr -121.41Cr -47Cr -594.53Cr -45Cr -44Cr -1.91TCr -467.47Cr -15Cr -13Cr -12Cr -11Cr -21Cr -1.41TCr -21Cr -147.27Cr -57Cr -721.19Cr -55Cr -54Cr -2.31TCr
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
02/26/02 NT$55.40 +0.18% 1,06,574
01/26/01 NT$55.30 -0.54% 1,96,339
30/26/30 NT$55.60 +0.36% 1,76,848
29/26/29 NT$55.40 -0.18% 1,14,431
24/26/24 NT$55.50 -1.25% 1,30,195
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock